Fig. 1From: Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy6-month PFS according to baseline TKa (with 95%CI) predicted by univariate model (a) and by multivariate model according to age or number of lines of chemotherapy (b)Back to article page